A new blood test can detect the GFAP protein at elevated levels in blood samples up to ten years before symptoms of Alzheimer's disease are first noticeable in those with an inherited form of the neurodegenerative disorder.
A new blood test can detect toxic amyloid beta oligomers associated with Alzheimer's disease years before symptoms appear.
A newly developed blood test for Alzheimer's disease measures a specific variant of the tau protein. Early results show the test has a good capacity to distinguish Alzheimer's disease from other tauopathies.
A new blood test for Alzheimer's disease is up-to 94% accurate at predicting dementia before symptoms appear. The test's accuracy is increased when genetic predisposition and age are taken into account. The new test may eventually replace PET neuroimaging, currently considered the gold standard, for early detection of Alzheimer's.
A new blood test to detect biomarkers for Alzheimer's disease is set to undergo trials in the Fall. The test will be able to identify traces of amyloid beta in blood samples with a high degree of accuracy.
Neurofilament light protein in plasma may be a noninvasive biomarker for neurodegeneration associated with Alzheimer's disease.
